Muphoran (Fotemustine)

Fotemustine belongs to the nitrosourea class of alkylating agents. It forms covalent cross‑links in DNA strands, preventing replication and transcription. This DNA damage triggers cell death, particularly in rapidly dividing cancer cells, and its ability to cross the blood‑brain barrier makes it effective for intracranial tumors.

The dosing regimen for Muphoran is individualized by the prescribing oncologist. Dosage depends on factors such as patient weight, renal and hepatic function, and the specific treatment protocol. Clinicians determine the appropriate amount and schedule for each patient.

Safety data for fotemustine during pregnancy and lactation are limited. Because of potential risks to the fetus and infant, Muphoran is generally avoided in pregnant or breastfeeding women unless the therapeutic benefit justifies the potential hazard. Consultation with a specialist is essential.

To order Muphoran, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and import documentation.

The primary alternative to fotemustine is temozolomide, another alkylating agent used for brain tumors. Fotemustine has higher lipophilicity, allowing better penetration of the blood‑brain barrier, but it is associated with a distinct toxicity profile, including higher rates of pulmonary fibrosis. Choice of therapy depends on tumor type, patient tolerance, and clinical judgment.

Muphoran must be stored at 2‑8 °C in a refrigerator. Keep the vials in their original packaging, protect them from light, and avoid freezing or shaking the solution. Ensure that the cold‑chain is maintained during transport to preserve product stability.

Muphoran is supplied as a sterile injection for intravenous infusion. It is administered by a qualified healthcare professional, typically over a period of 30‑60 minutes, according to the dosing schedule prescribed by the oncologist. Infusion rates may be adjusted based on patient tolerance.

Serious adverse events include pulmonary fibrosis, severe infections due to profound neutropenia, and hepatic toxicity manifested by elevated liver enzymes or liver failure. Patients should be monitored regularly for respiratory symptoms, signs of infection, and liver function abnormalities throughout treatment.

Muphoran is contraindicated in patients with severe bone‑marrow suppression, active uncontrolled infections, known hypersensitivity to fotemustine or other nitrosoureas, and in pregnant women unless the benefit outweighs the risk. Caution is also advised for individuals with significant hepatic or renal impairment.